Trials / Sponsors / Plus Therapeutics
Plus Therapeutics
Industry · 5 registered clinical trials — 4 currently recruiting.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Not Yet Recruiting | Determine Maximum Tolerated Dose, Safety, and Tolerability of Rhenium (186Re) in Pediatric Recurrent, Refracto Ependymoma, High Grade Gliomas | Phase 1 | 2025-09-01 |
| Recruiting | Multiple Dose Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases Leptomeningeal Metastasis | Phase 1 | 2025-07-02 |
| Recruiting | Safety & Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Patients Who Received a Prior 186RNL Glioma | Phase 1 | 2024-12-12 |
| Active Not Recruiting | Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases Leptomeningeal Metastasis | Phase 1 | 2021-12-06 |
| Recruiting | Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT) Glioma | Phase 1 / Phase 2 | 2015-06-03 |